43 / 66
23%
39%
39%
51%
100
90
80
70
60
50
40
30
10
0
20
27
18
15
9
6
21
12
3
0
24
30
OS (%)
Time (mos)
CheckMate 057 OS KM Curve (NSCLC)
During the first 3 months of treatment, a higher proportion of patients experienced death in the
nivolumab arm when compared with the docetaxel arm
Nivolumab
Docetaxel